25Nov 2023
Revvity Launches T-SPOT Test for Latent TB Screening in India

Revvity Launches T-SPOT Test for Latent TB Screening in India

Revvity launched its T-SPOT TB test for latent TB screening in India, presenting it at MICROCON in Lucknow. It is the only FDA-approved IGRA based on ELISPOT technology that standardizes results by isolating, washing, and counting blood cells. Particularly beneficial for challenging groups like the immunosuppressed, the test detects latent TB in a single visit, which is crucial in a country with 40% latent TB prevalence. Shripad Joshi, Revvity's President for India & South Asia, emphasized collaboration with India's healthcare sector for widespread integration, aligning with the government's goal to eradicate TB by 2025. The T-SPOT TB test follows WHO guidelines, offering accurate, cross-reactivity-free results.

  • #family health

Like

Save

Share